Investigator Initiated Trial: Colorectal Cancer with Fruquintinib

Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly’s commitment to improving the length and quality of people’s lives is achieved through its internal drug development programs and its support of Investigator Initiated Research.

Category

Therapeutic Area

Region

Learn More

Submission Countdown

Days
Hours
Apply Now

Fruquintinib is only available for use in studies based in China.

Focused on metastatic colorectal cancer with Fruquintinib alone or combined with other agents:

  • Earlier lines of systemic therapy
  • Subtypes not well represented in past or current trials
  • Precision medicine focused on potential biomarkers predicting response and/or resistance to Fruquintinib
  • RWS

Other tumor areas:

  • Multiple earlier phase investigations with Fruquintinib alone or combined with other agents

While these are our current areas of emphasis, all research questions are within scope except the following:

  • Trials competing with the medically approved Fruquintinib clinical development plan
  • Concepts that compete against ongoing Lilly-sponsored trials or future development plans
  • IITs seeking to examine alternate dosing regimens of Fruquintinib
PIRA™ suggested Proposal

PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.

Request PIRA™ to provide a suggested proposal